Report
CMV PCR monitoring in leucocytes of transplant patients

https://doi.org/10.1016/0928-0197(94)00028-SGet rights and content

Abstract

Background: The presumed latency of cytomegalovirus (CMV) in leucocytes and the sensitivity of the polymerase chain reaction (PCR) raise a question of its clinical value.

Objectives: To develop and standardize a CMV PCR as a diagnostic tool for CMV infection in solid organ and bone marrow transplant patients by comparing it to a likewise standardized isolation, rapid isolation and to clinical symptoms.

Study design: The material comprised 822 EDTA peripheral blood samples from 96 solid organ and 119 bone marrow transplant patients. One sample from each of 21 healthy bone marrow donors and 25 blood donors were used as controls. Two million leucocytes were lysed and one-tenth of a volume was used in a nested PCR employing immediate early gene primers.

Results: The limit of detection was ≈ 10 gene copies of a CMV DNA clone and 1 TCID50 of extracted DNA from a cell suspension. The specificity was ≥0.99 when tested in CMV seronegative individuals. The positive and negative predictive values were 0.62 and 1.00, respectively. When PCR was compared to virus isolation/rapid culture in individual patients, PCR was positive more frequently in solid organ transplant patients than was CMV isolation/rapid culture, but the difference was not significant in bone marrow transplant patients. In isolation-positive patients, PCR became positive in samples taken 1–2 weeks earlier. In 54 solid organ transplant patients with PCR-positive samples, CMV-associated symptoms were present in 2931 patients with CMV isolated from blood but in only 523 patients without viraemia. In 17 bone marrow transplant patients treated with ganciclovir, PCR became negative during or immediately after treatment in 1420 (70%) episodes. This was true of 512 (42%) solid organ transplant patients.

Conclusion: Screening of transplant patients with CMV PCR can be standardized at a clinically relevant level so that antiviral therapy can be instituted early.

References (38)

  • G.J. Demmler et al.

    Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification

    J. Infect. Dis.

    (1988)
  • R. Delgato et al.

    Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients

    J. Clin. Microbiol.

    (1992)
  • D.K. Dunn et al.

    Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir

    Transplantation

    (1991)
  • A. Ehrnst et al.

    Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease

    J. Med. Virol.

    (1993)
  • H.A. Erlich et al.

    HLA class II gene polymorphism: DNA typing, evolution and relationship to disease susceptibility

  • D. Faulds et al.

    Ganciclovir

    A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

    Drugs

    (1990)
  • G. Gerna et al.

    Monitoring of human cytomegalovirus and ganciclovir treatment in heart transplant recipients by determination of viraemia, antigenemia and DNAemia

    J. Infect. Dis.

    (1991)
  • C.A. Gleaves et al.

    Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens

    J. Clin. Microbiol.

    (1985)
  • J.M. Goodrich et al.

    Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

    New Engl. J. Med.

    (1991)
  • Cited by (0)

    View full text